When was NervGen founded?

NervGen was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is NervGen located?

NervGen is headquartered in Vancouver, Canada.

How many employees does NervGen have?

As of Aug 31, 2026, the latest employee count at NervGen is 17.

Is NervGen a funded company?

NervGen is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Nov 22, 2019.

When was the latest funding round of NervGen?

NervGen's latest funding was a $***** Grant (prize money) round on Oct 12, 2022, with participation from 1 investor.

Where does NervGen rank among its competitors?

NervGen ranks 491st amongst 2847 active competitors, of which 978 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of NervGen?

NervGen's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

NervGen - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of nerve damage. It has developed technology that targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that inhibits nerve regeneration. The company is developing candidate NVG-291, an inhibitor of the PTPσ receptor and being clinically tested for spinal cord injury.

Key Metrics

Founded Year

2016

Location

Vancouver, Canada

Stage

Public

Latest Funding Round

Grant (prize money), Oct 12, 2022, $*****

Investors

Military Health

Ranked

491^st among 2847 active competitors

Employee Count

17 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 567 more

Exit Details

Public

View NervGen's full profile

NervGen got listed on Feb 19, 2019.

Click here to take a look at NervGen's IPO in detail

NervGen has raised funding over 7 rounds. Its first funding round was on Nov 22, 2019. Its latest funding round was a Grant (prize money) round on Oct 12, 2022 for $*****. 1 investor participated in its latest round. NervGen has 1 institutional investor.

Here is the list of recent funding rounds of NervGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 12, 2022	2945334	Grant (prize money)	9104855	4008870	5093535	6120889
Jul 14, 2022	2979171	Post IPO	4029892	5806791	5428354	5409873
Dec 08, 2021	6920691	Post IPO	1809526	4059739	3025911	6869573

Access funding benchmarks and valuations. Sign up today!

View details of NervGen's funding rounds and investors

NervGen's employee count trend

NervGen has 17 employees as of Aug 26. Here is NervGen's employee count trend over the years:

Uncover NervGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NervGen include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of NervGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
491st	NervGen 2016, Vancouver (Canada), Public	Developer of therapeutics for the treatment of nerve damage	-	Military Health	47/100